ES2425448B8 - Uso de la obestatina para la regeneración muscular - Google Patents

Uso de la obestatina para la regeneración muscular Download PDF

Info

Publication number
ES2425448B8
ES2425448B8 ES201230367A ES201230367A ES2425448B8 ES 2425448 B8 ES2425448 B8 ES 2425448B8 ES 201230367 A ES201230367 A ES 201230367A ES 201230367 A ES201230367 A ES 201230367A ES 2425448 B8 ES2425448 B8 ES 2425448B8
Authority
ES
Spain
Prior art keywords
muscle regeneration
obestatine
regeneration
muscle
obestatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201230367A
Other languages
English (en)
Other versions
ES2425448B2 (es
ES2425448A1 (es
Inventor
Jesús PÉREZ CAMIÑA
Felipe CASANUEVA FREIJO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade de Santiago de Compostela
Servizo Galego de Saude SERGAS
Original Assignee
Universidade de Santiago de Compostela
Servizo Galego de Saude SERGAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade de Santiago de Compostela, Servizo Galego de Saude SERGAS filed Critical Universidade de Santiago de Compostela
Priority to ES201230367A priority Critical patent/ES2425448B8/es
Priority to US14/384,766 priority patent/US20150094264A1/en
Priority to PCT/ES2013/070149 priority patent/WO2013135928A1/es
Priority to EP13761384.0A priority patent/EP2862577B1/en
Publication of ES2425448A1 publication Critical patent/ES2425448A1/es
Application granted granted Critical
Publication of ES2425448B2 publication Critical patent/ES2425448B2/es
Publication of ES2425448B8 publication Critical patent/ES2425448B8/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2214—Motilins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de la obestatina para la regeneración muscular.#La presente invención se refiere al uso de la obestatina, o a la secuencia nucleotídica que la codifica, como agente miogénico “in vitro”, y para la elaboración de un medicamento para la regeneración muscular preferiblemente para la regeneración músculo-esquelética, siendo así de utilidad en el tratamiento y/o prevención de enfermedades degenerativas o genéticas o de lesiones que cursan con daño muscular.
ES201230367A 2012-03-12 2012-03-12 Uso de la obestatina para la regeneración muscular Expired - Fee Related ES2425448B8 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES201230367A ES2425448B8 (es) 2012-03-12 2012-03-12 Uso de la obestatina para la regeneración muscular
US14/384,766 US20150094264A1 (en) 2012-03-12 2013-03-08 Use of obestatin for muscle regeneration
PCT/ES2013/070149 WO2013135928A1 (es) 2012-03-12 2013-03-08 Uso de la obestatina para la regeneración muscular
EP13761384.0A EP2862577B1 (en) 2012-03-12 2013-03-08 Use of obestatin for muscle regeneration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201230367A ES2425448B8 (es) 2012-03-12 2012-03-12 Uso de la obestatina para la regeneración muscular

Publications (3)

Publication Number Publication Date
ES2425448A1 ES2425448A1 (es) 2013-10-15
ES2425448B2 ES2425448B2 (es) 2014-11-07
ES2425448B8 true ES2425448B8 (es) 2015-03-17

Family

ID=49160293

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201230367A Expired - Fee Related ES2425448B8 (es) 2012-03-12 2012-03-12 Uso de la obestatina para la regeneración muscular

Country Status (4)

Country Link
US (1) US20150094264A1 (es)
EP (1) EP2862577B1 (es)
ES (1) ES2425448B8 (es)
WO (1) WO2013135928A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020058533A1 (en) * 2018-09-21 2020-03-26 Universidade De Santiago De Compostela Obestatin for use in the treatment of peripheral nerve damages or injuries

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60142511D1 (de) * 2000-05-11 2010-08-19 Zymogenetics Inc Zsig33-ähnliche peptide
EP1861416A1 (en) * 2005-03-09 2007-12-05 The Board of Trustees of Leland Stanford Junior University Obestatin and its uses
US20100190717A1 (en) * 2007-09-11 2010-07-29 Dorian Bevec Use of melanin concentrating hormone and met-enkephalin as therapeutic agents
JP2010539007A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのペプチドの使用
MX2011003117A (es) * 2008-09-19 2011-04-21 Nektar Therapeutics Conjugados polimericos de peptidos terapeuticos.

Also Published As

Publication number Publication date
US20150094264A1 (en) 2015-04-02
EP2862577A1 (en) 2015-04-22
WO2013135928A1 (es) 2013-09-19
EP2862577B1 (en) 2017-08-02
ES2425448B2 (es) 2014-11-07
ES2425448A1 (es) 2013-10-15
EP2862577A4 (en) 2015-11-11

Similar Documents

Publication Publication Date Title
HK1211483A1 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX2020001201A (es) Anticuerpos anti-activina a y usos de los mismos.
MX382516B (es) Composiciones y metodos para absorcion transmucosa.
IN2015DN03219A (es)
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
CL2014003388A1 (es) Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades.
CL2015000331A1 (es) Compuestos derivados de piridazina 1,4-disustitutidos; composicion y combinacion farmaceutica que los comprende y uso en el tratamiento de la atrofia muscular espinal.
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
CL2012002175A1 (es) Composicion farmaceutica oral de liberacion prolongada que comprende un agente activo de fracciones de propargilamina y aminoindano; metodo de preparacion; uso en el tratamiento de enfermedades neurodegenerativas o lesiones en el sistema nervioso tales como parkinson o alzheimer, un accidente cerebrovascular o lesion traumatica cerebral.
WO2013151665A3 (en) Modified polynucleotides for the production of proteins associated with human disease
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
BR112012022552A2 (pt) uso de fenoterol e de anélogos de fenoterol no tratamento de gliobastomas e astrocitomas
MX339205B (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
CY1116304T1 (el) Χρηση της βιοτινης για τη θεραπευτικη αγωγη της σκληρυνσης κατα πλακας
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
MX2014008706A (es) Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
BR112014021497A2 (pt) sistema de entrega de fármaco baseado em jcv-vlp
WO2013173827A3 (en) Methods and compositions for inhibiting diseases of the central nervous system
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
CL2014001776A1 (es) Composicion farmaceutica topica que comprende: a) bexaroteno, b) al menos 1 corticosteroide y c) un portador o vehiculo; uso para el tratamiento o la prevencion de trastornos de la piel, como psoriasis.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
PE20151424A1 (es) Compuesto farmaceutico para la prevencion y el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2425448

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20141107

FD2A Announcement of lapse in spain

Effective date: 20210928